Specify a stock or a cryptocurrency in the search bar to get a summary
NicOx S.A.
ALCOXNicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. Nicox S.A. is developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France. Address: Sundesk Sophia Antipolis, Valbonne, France, 06410
Analytics
WallStreet Target Price
0.92 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALCOX
Dividend Analytics ALCOX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALCOX
Stock Valuation ALCOX
Financials ALCOX
Results | 2019 | Dynamics |